Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Losartan + atorvastatin is a fixed-dose combination of two small molecule drugs used to treat patients with both hypertension and hypercholesterolemia. Losartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the binding of angiotensin II to the type 1 angiotensin II receptor, resulting in vasodilation. Atorvastatin is a statin that inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver and lowering blood lipid levels. The combination provides additive or synergistic cardiovascular protection, improving endothelial function and reducing risk factors for heart attack and stroke. Mechanistically, their combined effect may be mediated through increased nitric oxide bioavailability in vascular endothelium, leading to improved vasorelaxation and cardioprotection[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Losartan + atorvastatin.